Document is current

Article History

Received: 28 March 2025

Accepted: 3 July 2025

First Online: 5 August 2025

Declarations

:

: All experimental procedures involving iPSCs were approved by the Ethics Committee of Beijing Luhe Hospital. The research project titled “Peripheral blood collection from healthy people for iPSC cell bank construction and clinical use” was approved on July 24, 2023 (2021-LHYW-043-04). Donors provided written informed consent for their participation in the study and the use of their tissue for research purposes. Human dermal fibroblasts were purchased from a commercial vendor, IMMOCELL. The company has confirmed that there was initial ethical approval for the collection of human materials and the derivation of cell lines and that the donors had signed informed consent. See for details: .All experimental procedures involving MSC cells approved by the Ethics Committee of Tsinghua Changgung Hospital. The research project titled “Clinical study on the safety, tolerability and preliminary efficacy of mesenchymal stem cell derived exosomes in the treatment of idiopathic pulmonary fibrosis” was approved on July 31, 2023 (No.23346-4-02). Donors provided written informed consent for their participation in the study and the use of their tissue for research purposes.All animal procedures were performed in accordance with relevant laws and regulations governing the use and care of experimental animals and approved by the Institutional Animal Care and Use Committee (IACUC) of Allife Medicine (No. IAUCC-2024-160, Title: Safety and efficacy of mesenchymal stem cell-derived exosomes in the treatment of pulmonary fibrosis in mice; Date of approval: Feb 1, 2024).

: All authors confirm their consent for publication.

: This study was partially supported by Allife Medicne, Inc. Other authors declare no conflict of interest.